Mallinckrodt to acquire Questcor Pharmaceuticals for $5.6 billion
MLex Summary: NYSE-listed global specialty pharmaceuticals company Mallinckrodt has agreed to acquire Nasdaq-listed drug company Questcor Pharmaceuticals for $5.6 billion. The deal is expected to close in the third quarter of this year.Statement follows in full....To view the full article, register now.
Already a subscriber? Click here to view full article